Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

500 patients join biobank to unlock secrets of rare brain vessel diseases

NCT ID NCT07264972

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study collects blood and urine samples from 500 people with rare brain vessel diseases, such as CADASIL and moya-moya. Researchers aim to find biomarkers that could improve care or identify new treatment targets. Participants are already part of an existing rare disease cohort, and samples will be stored for future research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify new biomarkers to improve diagnosis and treatment for rare brain vessel diseases.
What could go wrong
This is an observational biobank study, not a treatment trial. It may not directly lead to new therapies, and results may take years to impact patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Jan 2021

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with rare cerebrovascular diseases

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of a rare cerebral vascular disease of the brain, including: Familial intracranial aneurysms, cerebral amyloid angiopathy, CADASIL, familial cerebral cavernoma, familial cervical or intracranial artery dissection, vascular leukoencephalopathy (hereditary), familial hemiplegic migraine, cerebral arteriovenous malformation, moya-moya, cerebral venous thrombosis, hereditary retinal tortuosity, cerebro-retinal vasculopathies, other known rare diseases, or other rare diseases that are undetermined or not yet described. * Participation in the MVCR cohort * Adults \>18 years old * Affiliation with French social security or beneficiary - Signature of informed consent Exclusion Criteria: * Incompatibility with long-term follow-up at CERVCO * Patient under guardianship/conservatorship * Pregnant or breastfeeding women * Patient under AME

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebrovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebrovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebrovascular disease

Contacts and locations

Locations

  • Lariboisière hospital

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.